<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537612</url>
  </required_header>
  <id_info>
    <org_study_id>CAN1701</org_study_id>
    <nct_id>NCT03537612</nct_id>
  </id_info>
  <brief_title>Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain</brief_title>
  <acronym>RCT</acronym>
  <official_title>Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Jean A. Ouellet, MD, FRCSC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this proposal is to determine if quantitative sensory testing (QST)&#xD;
      assessing pain modulation can be used as a clinical tool to optimize perioperative pain&#xD;
      management. The central hypothesis is that the identification of patient's sensory pain&#xD;
      profile allows personalizing therapeutic approaches to improve individualized pain management&#xD;
      and thus prevents pain chronicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate if pre-operative QST can identify if&#xD;
      patients will have high pain intensity peri-operatively and at 6 months post-operatively.&#xD;
      Evaluation of the intensity and chronicity of pain and the function of the descending&#xD;
      inhibitory system through a short QST procedure before surgery and six months after surgery&#xD;
      will be carried out. In addition, evaluation of the patient's physical and emotional&#xD;
      functioning, and exploration of the potential biological underlying mechanisms will also be&#xD;
      assessed at the same time points.&#xD;
&#xD;
      The secondary objective of this study is to determine if the peri-operative use of an alpha-2&#xD;
      adrenergic receptor agonist enhances the efficacy of the descending inhibitory system of&#xD;
      patients with sub-optimal CPM efficacy before surgery by decreasing pain after surgery.&#xD;
      Consequently, this pharmacological intervention may also reduce the incidence of acute and&#xD;
      chronic pain after surgery. Evaluation of the pain intensity and the function of the&#xD;
      descending inhibitory system through a short QST procedure six weeks after surgery and six&#xD;
      months after surgery in patients receiving Clonidine or placebo during the perioperative&#xD;
      period will be done. In addition, evaluation of the patient's physical and emotional&#xD;
      functioning, and exploration the potential biological underlying mechanisms at the same time&#xD;
      points will be assessed.&#xD;
&#xD;
      Lastly, evaluation of potential biomechanical alterations in 3D related to pain in children&#xD;
      reporting presence of back pain pre and post spine surgery will be looked at.&#xD;
&#xD;
      The hypothesis is that patients undergoing spine surgery with poor inhibitory pain response&#xD;
      will have less pain in the immediate and long-term period when treated prophylactically with&#xD;
      Clonidine in the perioperative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new&#xD;
    sponsor and protocol modifications&#xD;
  </why_stopped>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QST</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate if pre-operative QST can identify if patients will have high pain intensity peri-operatively and at 6 months post-operatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clonidine</measure>
    <time_frame>6 months</time_frame>
    <description>Peri-operative use of an alpha-2 adrenergic receptor agonist enhances the efficacy of the descending inhibitory system of patients with sub-optimal CPM efficacy before surgery by decreasing pain after surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>3D Images 3D Biomechanical Alterations</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the potential biomechanical alterations in 3D related to pain in children reporting presence of back pain pre and post spine surgery.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Scoliosis</condition>
  <arm_group>
    <arm_group_label>Opt-Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-opt-Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opt-Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-opt-Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)</description>
    <arm_group_label>Opt-Clonidine</arm_group_label>
    <arm_group_label>Sub-opt-Clonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)</description>
    <arm_group_label>Opt-Morphine</arm_group_label>
    <arm_group_label>Sub-opt-Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females* aged between 10 and 21 years old&#xD;
&#xD;
          -  Scheduled to undergo anterior or posterior spinal fusion surgery for AIS with&#xD;
             instrumentation&#xD;
&#xD;
          -  Ability to adequately understand and respond to outcome measures&#xD;
&#xD;
          -  No previous major orthopedic surgery&#xD;
&#xD;
          -  Any ethnic background&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with history of allergies to Clonidine or it's excipients in either injection&#xD;
             or tablet formulation (see respective monograph)&#xD;
&#xD;
          -  Children with history of galactose intolerance&#xD;
&#xD;
          -  Children with history of myocardial disease, arrhythmias, cerebrovascular disease,&#xD;
             Raynaud's/Thromboangiitis obliterans or chronic renal failure diagnosis based on&#xD;
             history and physical&#xD;
&#xD;
          -  Children taking anti-hypertensive agents (diuretics, vasodilators, beta-blockers,&#xD;
             ace-inhibitors)&#xD;
&#xD;
          -  History of depression&#xD;
&#xD;
          -  Inability of the child to speak English or French&#xD;
&#xD;
          -  Diagnosed with developmental delay that would interfere with understanding the&#xD;
             questions being asked (autism, mental retardation)&#xD;
&#xD;
          -  Children with major chronic medical conditions (ASA status III or higher)&#xD;
&#xD;
          -  Pregnancy excluded by an in hospital testing the night before surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean A Ouellet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospital for Children - Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Hospitals for Children - Canada</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shriners Hospitals for Children</investigator_affiliation>
    <investigator_full_name>Dr. Jean A. Ouellet, MD, FRCSC</investigator_full_name>
    <investigator_title>Deputy Chief of Staff</investigator_title>
  </responsible_party>
  <keyword>Post-operative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03537612/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

